Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications

The brain-gut axis represents one of the most important communication pathways in the body, and BPC-157 appears to be uniquely positioned to leverage this connection for therapeutic benefit. This comprehensive review by Sikiric, Seiwerth, Rucman, and colleagues, published in Current Neuropharmacology, examines the theoretical and practical implications of BPC-157's activity across both the gut and the central nervous system.

The authors conducted an extensive literature review examining BPC-157's effects on the brain-gut axis, drawing from decades of preclinical research. They analyzed studies covering traumatic brain injury, spinal cord compression, peripheral nerve damage, dopaminergic and serotonergic system modulation, and gastrointestinal healing.

The review revealed that BPC-157 provides remarkable neuroprotection across multiple models. It improved outcomes in traumatic brain injury and spinal cord compression, promoted peripheral nerve regeneration, and modulated both dopaminergic and serotonergic neurotransmitter systems. The peptide also counteracted toxicity from NSAIDs, insulin overdose, and paracetamol, while simultaneously healing gastrointestinal lesions — all without reported toxicity.

These findings position BPC-157 as far more than a gut-healing peptide. By demonstrating activity across the brain-gut axis, this review supports its potential as a systemic therapeutic agent with applications ranging from neurological conditions to mood disorders. The absence of reported toxicity in preclinical studies further strengthens its appeal as a versatile peptide therapy.